n/a
Article Publish Status: FREE
Abstract Title:

Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy.

Abstract Source:

J Res Med Sci. 2019 ;24:77. Epub 2019 Aug 28. PMID: 31523263

Abstract Author(s):

Azam Vanaie, Shahrzad Shahidi, Bijan Iraj, Zahra Dana Siadat, Mansure Kabirzade, Feloria Shakiba, Mohsen Mohammadi, Homeira Parvizian

Article Affiliation:

Azam Vanaie

Abstract:

Background: Diabetic nephropathy (DN) is a common cause of end-stage renal disease (ESRD). The benefits and effects of renin-angiotensin system blocker drugs are obvious in decreasing albuminuria, but there is a need to find other drugs that can decrease albuminuria. The aim of our study is to evaluate the effect of short-term administration of curcumin on overt albuminuria in patients with type 2 diabetes mellitus (T2DM).

Materials and Methods: A randomized, double-blind clinical trial was performed on 46 patients with T2DM, overt albuminuria≥300 mg/24 h, and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m. After the random allocation of the patients, they were divided into two groups. In the curcumin group, the patients received 500 mg (one capsule) of curcumin with each meal (three times/day after meal) for 16 weeks. Other variables including blood urea nitrogen (BUN), creatinine (Cr), fasting blood sugar (FBS), 2-h postprandial blood sugar (2-h pp BS), lipid profile, 24-h urine analysis for albuminuria, serum albumin, and hemoglobin A1C (HbA1C) were checked at baseline and bimonthly too.

Results: two groups at baseline were comparable in terms of basic characteristics (>0.05). Albuminuria decreased significantly from 900.42± 621.91 at the baseline to 539.68 ± 375.16 at the end of the study in the curcumin group (= 0.002); however, no statistically significant changes were observed in the placebo group (519.94± 214.33 at the baseline vs. 444.00 ± 219.10 at the end of the trial;= 0.43), and the decrease was significantly higher in the curcumin group than that of the placebo group (= 0.01). No significant differences were observed between the placebo and curcumin in terms of changes in serum BUN, Cr, FBS, 2-h pp BS, HbA1C, lipid profile, and albumin.

Conclusion: Our study showed that curcumin as an active turmeric metabolite was an effective adjuvant therapy for ameliorating macroscopic proteinuria in type 2 diabetic patients. Its effect may appear after 2 months of therapy and even in patients with a mild decrease in GFR. Further studies with larger sample size and longer duration are recommended.

Study Type : Human Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2020 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.